Vaxart, Inc.

NasdaqCM:VXRT Stock Report

Market Cap: US$213.9m

Vaxart Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Steven Lo

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3.2yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%

Jan 04
Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Ray Stapleton joins Vaxart as CTO

Aug 31

Vaxart shareholders approve proposal to increase number of shares

Aug 05

Vaxart continues to lobby shareholders to vote to increase number of shares

Jul 29

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

CEO

Steven Lo (57 yo)

less than a year

Tenure

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Sean Tucker
Senior VP & Chief Scientific Officer14.9yrsUS$1.14m0.10%
$ 222.7k
James Cummings
Chief Medical Officer3.4yrsUS$1.17m0.063%
$ 135.5k
Steven Lo
Presidentless than a yearno datano data
Phillip Eric Lee
CFO, Principal Financial Officer & Principal Accounting Officer2.1yrsno data0.041%
$ 86.9k
Raymond Stapleton
Chief Technology Officer2.4yrsno datano data
Edward Berg
Senior VP & General Counsel2.9yrsno data0.050%
$ 106.5k
Shaily Garg
Senior Vice President of Clinical Development & Project Management4.8yrsno datano data
Rajesh Kapoor
Senior Vice President of Quality4yrsno datano data

3.2yrs

Average Tenure

56.5yo

Average Age

Experienced Management: VXRT's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steven Lo
Presidentless than a yearno datano data
Robert Yedid
Independent Director5.3yrsUS$92.26k0.0081%
$ 17.4k
Harry Greenberg
Member of Scientific & Clinical Advisory Board3.4yrsno datano data
Elaine Heron
Independent Director2.4yrsUS$89.08k0.011%
$ 23.1k
Michael Finney
Independent Chairman of the Board6.9yrsUS$109.57k0.29%
$ 630.8k
Stefan Gravenstein
Member of Scientific & Clinical Advisory Board3.4yrsno datano data
David Wheadon
Independent Director3.8yrsUS$93.72k0.0065%
$ 13.9k
Robert Belshe
Member of Scientific & Clinical Advisory Board3.4yrsno datano data
William Watson
Independent Director2.4yrsUS$94.76k0.023%
$ 49.2k
Marion Pepper
Member of Scientific & Clinical Advisory Board3.4yrsno datano data
Ralph Baric
Member of Scientific & Clinical Advisory Board3.4yrsno datano data
Gregory Gray
Member of Scientific & Clinical Advisory Board3.4yrsno datano data

3.4yrs

Average Tenure

66yo

Average Age

Experienced Board: VXRT's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 05:51
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vaxart, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Charles DuncanCantor Fitzgerald & Co.
Vernon BernardinoH.C. Wainwright & Co.